Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

NCT ID: NCT01386008

Last Updated: 2019-09-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the performance of the investigational CooperVision silicone hydrogel lens compared to a currently-marketed silicone hydrogel contact lens up to 30 days of daily lens wear.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

enfilcon A + senofilcon A

Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other

Group Type OTHER

senfilcon A contact lens

Intervention Type DEVICE

senofilcon A spherical contact lens worn in a daily wear modality

investigational enfilcon A

Intervention Type DEVICE

investigational enfilcon A, worn daily wear modality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

senfilcon A contact lens

senofilcon A spherical contact lens worn in a daily wear modality

Intervention Type DEVICE

investigational enfilcon A

investigational enfilcon A, worn daily wear modality

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be at least 18 years of age as of the date of evaluation for the study.
2. Not using any ocular medications
3. Have a self-reported full eye examination within 2 years.
4. Have:

* read the Informed Consent
* be given an explanation of the Informed Consent
* indicate understanding of the Informed Consent
* signed the Informed Consent document.
5. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
6. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
7. Possess wearable and visually functional eyeglasses.
8. Be in good general health, based on his/her knowledge.
9. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less.
10. Be willing to wear contact lenses in both eyes.
11. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye.
12. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion Criteria

1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
2. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study.
3. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month.
4. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study.
5. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea.
6. Is aphakic or pseudophakic.
7. Unable to achieve a satisfactory fit with the lens designs used in the study
8. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
9. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day.
10. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures.
11. A history of herpetic keratitis.
12. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection.
13. A history of papillary conjunctivitis that has interfered with contact lens wear.
14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

* Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> grade 2
* Pterygium
* Corneal scars within the visual axis
* Corneal edema or corneal staining ≥ grade 2
* Neovascularization or ghost vessels \> 1.0 mm in from the limbus
* Giant papillary conjunctivitis (GPC) of \> grade 2.
* Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center, University of California, Berkeley

Berkeley, California, United States

Site Status

University of Manchester

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV-10-50

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.